Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose and food-effect study of oral CG-549 tablets in healthy volunteers
NL-OMON48209Active, not recruiting
- Sponsor
- Crystal Genomics
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of nilofabicin in bacterial disease and Staphylococcus aureus infection (2 arms), sponsored by Crystal Genomics. Primary endpoints: Plasma CG-549 concentrations, Urine CG-549 concentrations and 10 more. Started Sep 2019; status: active, not recruiting.
02
Drugs
nilofabicin
03
Conditions
bacterial diseaseStaphylococcus aureus infection
Beyond the preview
Go deeper on NL-OMON48209.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON48209.